Phreesia, Inc. (NYSE:PHR) General Counsel Sells $105,961.02 in Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 3,982 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $26.61, for a total value of $105,961.02. Following the sale, the general counsel now directly owns 159,137 shares in the company, valued at approximately $4,234,635.57. This represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Phreesia Price Performance

PHR stock opened at $26.75 on Friday. The stock has a market cap of $1.55 billion, a PE ratio of -18.20 and a beta of 0.94. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $29.16. The company has a 50-day moving average price of $22.87 and a 200 day moving average price of $22.62. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. During the same quarter in the previous year, the business earned ($0.58) earnings per share. The company’s revenue for the quarter was up 16.6% compared to the same quarter last year. Equities research analysts anticipate that Phreesia, Inc. will post -1.16 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on PHR shares. Robert W. Baird decreased their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. KeyCorp boosted their target price on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday. Citigroup raised their target price on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday. Truist Financial boosted their price target on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, JMP Securities restated a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research report on Tuesday, December 10th. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $31.00.

Institutional Trading of Phreesia

Hedge funds and other institutional investors have recently bought and sold shares of the business. Deerfield Management Company L.P. Series C bought a new stake in shares of Phreesia during the second quarter valued at approximately $4,078,000. Champlain Investment Partners LLC raised its position in Phreesia by 4.1% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock valued at $57,062,000 after purchasing an additional 97,847 shares in the last quarter. Sei Investments Co. lifted its holdings in shares of Phreesia by 135.3% in the 2nd quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock worth $3,505,000 after buying an additional 95,058 shares during the period. Squarepoint Ops LLC grew its position in shares of Phreesia by 56.3% during the 2nd quarter. Squarepoint Ops LLC now owns 250,396 shares of the company’s stock worth $5,308,000 after buying an additional 90,215 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Phreesia by 7.1% during the third quarter. State Street Corp now owns 1,327,586 shares of the company’s stock valued at $30,256,000 after buying an additional 88,517 shares during the period. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.